|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jin P, Wu ZT, Li SR, Li SJ, Wang JH, Wang
ZH, Lu JG, Cui XJ, Han Y, Rao J and Sheng JQ: Colorectal cancer
screening with fecal occult blood test: A 22-year cohort study.
Oncol Lett. 6:576–582. 2013.PubMed/NCBI
|
|
3
|
André T, Boni C, Mounedji-Boudiaf L,
Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan
P, Bridgewater J, et al: Oxaliplatin, fluorouracil and leucovorin
as adjuvant treatment for colon cancer. N Engl J Med.
350:2343–2351. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Verhoef MJ, Balneaves LG, Boon HS and
Vroegindewey A: Reasons for and characteristics associated with
complementary and alternative medicine use among adult cancer
patients: A systematic review. Integr Cancer Ther. 4:274–286. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Boon H and Wong J: Botanical medicine and
cancer: A review of the safety and efficacy. Expert Opin
Pharmacother. 5:2485–2501. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Fish JM, Welchons DR, Kim YS, Lee SH, Ho
WK and Antzelevitch C: Dimethyl lithospermate b, an extract of
danshen, suppresses arrhythmogenesis associated with the brugada
syndrome. Circulation. 113:1393–1400. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chang PN, Mao JC, Huang SH, Ning L, Wang
ZJ, On T, Duan W and Zhu YZ: Analysis of cardioprotective effects
using purified Salvia miltiorrhiza extract on isolated rat
hearts. J Pharmacol Sci. 101:245–249. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Che AJ, Zhang JY, Li CH, Chen XF, Hu ZD
and Chen XG: Separation and determination of active components in
Radix Salviae miltiorrhizae and its medicinal preparations
by nonaqueous capillary electrophoresis. J Sep Sci. 27:569–575.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhou L, Zuo Z and Chow MS: Danshen: An
overview of its chemistry, pharmacology, pharmacokinetics and
clinical use. J Clin Pharmacol. 45:1345–1359. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jang SI, Kim HJ, Kim YJ, Jeong SI and You
YO: Tanshinone IIA inhibits LPS-induced NF-kappaB activation in raw
264.7 cells: Possible involvement of the NIK-IKK, ERK1/2, P38 and
JNK pathways. Eur J Pharmacol. 542:1–7. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li W, Li J, Ashok M, Wu R, Chen D, Yang L,
Yang H, Tracey KJ, Wang P, Sama AE and Wang H: A cardiovascular
drug rescues mice from lethal sepsis by selectively attenuating a
late-acting proinflammatory mediator, high mobility group box 1. J
Immunol. 178:3856–3864. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lin R, Wang WR, Liu JT, Yang GD and Han
CJ: Protective effect of tanshinone IIA on human umbilical vein
endothelial cell injured by hydrogen peroxide and its mechanism. J
Ethnopharmacol. 108:217–222. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang AM, Sha SH, Lesniak W and Schacht J:
Tanshinone (Salviae miltiorrhizae extract) preparations
attenuate aminoglycoside-induced free radical formation in vitro
and ototoxicity in vivo. Antimicrob Agents Chemother. 47:1836–1841.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tian HL, Yu T, Xu NN, Feng C, Zhou LY, Luo
HW, Chang DC, Le XF and Luo KQ: A novel compound modified from
tanshinone inhibits tumor growth in vivo via activation of the
intrinsic apoptotic pathway. Cancer Lett. 297:18–30. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang J, Wang J, Jiang JY, Liu SD, Fu K
and Liu HY: Tanshinone IIA induces cytochrome c-mediated caspase
cascade apoptosis in A549 human lung cancer cells via the JNK
pathway. Int J Oncol. 45:683–690. 2014.PubMed/NCBI
|
|
16
|
Yun SM, Jung JH, Jeong SJ, Sohn EJ, Kim B
and Kim SH: Tanshinone IIA induces autophagic cell death via
activation of AMPK and ERK and inhibition of mTOR and p70 S6k in
KBM-5 leukemia cells. Phytother Res. 28:458–464. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yang L, Guo H, Dong L, Wang L, Liu C and
Wang X: Tanshinone IIA inhibits the growth, attenuates the stemness
and induces the apoptosis of human glioma stem cells. Oncol Rep.
32:1303–1311. 2014.PubMed/NCBI
|
|
18
|
Su CC, Chen GW, Kang JC and Chan MH:
Growth inhibition and apoptosis induction by tanshinone IIA in
human colon adenocarcinoma cells. Planta Med. 74:1357–1362. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Luo P, Tan Z, Zhang Z, Li H and Mo Z:
Inhibitory effects of salvianolic acid B on the high
glucose-induced mesangial proliferation via NF-kappaB-dependent
pathway. Biol Pharm Bull. 31:1381–1386. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lui VW, Boehm AL, Koppikar P, Leeman RJ,
Johnson D, Ogagan M, Childs E, Freilino M and Grandis JR:
Antiproliferative mechanisms of a transcription factor decoy
targeting signal transducer and activator of transcription (stat)
3. The role of stat1. Mol Pharmacol. 71:1435–1443. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chen SJ: A potential target of Tanshinone
IIA for acute promyelocytic leukemia revealed by inverse docking
and drug repurposing. Asian Pac J Cancer Prev. 15:4301–4305. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chiu SC, Huang SY, Chen SP, Su CC, Chiu TL
and Pang CY: Tanshinone IIA inhibits human prostate cancer cells
growth by induction of endoplasmic reticulum stress in vitro and in
vivo. Prostate Cancer Prostatic Dis. 16:315–322. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Won SH, Lee HJ, Jeong SJ, Lü J and Kim SH:
Activation of p53 signaling and inhibition of androgen receptor
mediate tanshinone IIA induced G1 arrest in LNCaP prostate cancer
cells. Phytother Res. 26:669–674. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kan S, Cheung WM, Zhou Y and Ho WS:
Enhancement of doxorubicin cytotoxicity by tanshinone IIA in HepG2
human hepatoma cells. Planta Med. 80:70–76. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fu P, Du F, Chen W, Yao M, Lv K and Liu Y:
Tanshinone IIA blocks epithelial-mesenchymal transition through
HIF-1α downregulation, reversing hypoxia-induced chemotherapy
resistance in breast cancer cell lines. Oncol Rep. 31:2561–2568.
2014.PubMed/NCBI
|
|
26
|
Housman G, Byler S, Heerboth S, Lapinska
K, Longacre M, Snyder N and Sarkar S: Drug resistance in cancer: An
overview. Cancers (Basel). 6:1769–1792. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Garg A and Aggarwal BB: Nuclear
transcription factor-kappaB as a target for cancer drug
development. Leukemia. 16:1053–1068. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yu HG, Yu LL, Yang Y, Luo HS, Yu JP, Meier
JJ, Schrader H, Bastian A, Schmidt WE and Schmitz F: Increased
expression of RelA/nuclear factor-kappa B protein correlates with
colorectal tumorigenesis. Oncology. 65:37–45. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liptay S, Weber CK, Ludwig L, Wagner M,
Adler G and Schmid RM: Mitogenic and antiapoptotic role of
constitutive NF-kappaB/Rel activity in pancreatic cancer. Int J
Cancer. 105:735–746. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Nair A, Venkatraman M, Maliekal TT, Nair B
and Karunagaran D: Nf-kappaB is constitutively activated in
high-grade squamous intraepithelial lesions and squamous cell
carcinomas of the human uterine cervix. Oncogene. 22:50–58. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li W, Tan D, Zenali MJ and Brown RE:
Constitutive activation of nuclear factor-kappa B (NF-κB) signaling
pathway in fibrolamellar hepatocellular carcinoma. Int J Clin Exp
Pathol. 3:238–243. 2010.
|
|
32
|
Nagel D, Vincendeau M, Eitelhuber AC and
Krappmann D: Mechanisms and consequences of constitutive nf-kappab
activation in B-cell lymphoid malignancies. Oncogene. 11:5655–5565.
2014. View Article : Google Scholar
|
|
33
|
Shishodia S, Amin HM, Lai R and Aggarwal
BB: Curcumin (diferuloylmethane) inhibits constitutive NF-kappaB
activation, induces G1/s arrest, suppresses proliferation and
induces apoptosis in mantle cell lymphoma. Biochem Pharmacol.
70:700–713. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Baldwin AS: Control of oncogenesis and
cancer therapy resistance by the transcription factor NF-kappaB. J
Clin Invest. 107:241–246. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
35
|
Shen HM and Tergaonkar V: NFkappaB
signaling in carcinogenesis and as a potential molecular target for
cancer therapy. Apoptosis. 14:348–363. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Li X, Yang G, Li X, Zhang Y, Yang J, Chang
J, Sun X, Zhou X, Guo Y, Xu Y, et al: Traditional Chinese medicine
in cancer care: A review of controlled clinical studies published
in chinese. PloS One. 8:e603382013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Shang Q, Xu H and Huang L: Tanshinone IIA.
A promising natural cardioprotective agent. Evid Based Complement
Alternat Med. 2012:7164592012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Jiang FL, Leo S, Wang XG, Li H, Gong LY,
Kuang Y and Xu XF: Effect of tanshinone IIA on cardiomyocyte
hypertrophy and apoptosis in spontaneously hypertensive rats. Exp
Ther Med. 6:1517–1521. 2013.PubMed/NCBI
|
|
39
|
Jin HJ and Li CG: Tanshinone IIA and
cryptotanshinone prevent mitochondrial dysfunction in
hypoxia-induced H9c2 cells: Association to mitochondrial ROS,
intracellular nitric oxide and calcium levels. Evid Based
Complement Alternat Med. 2013:6106942013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Jin HJ, Xie XL, Ye JM and Li CG:
Tanshinoneiia and cryptotanshinone protect against hypoxia-induced
mitochondrial apoptosis in H9c2 cells. PLoS One. 8:e517202013.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Jung JH, Kwon TR, Jeong SJ, Kim EO, Sohn
EJ, Yun M and Kim SH: Apoptosis induced by tanshinone IIA and
cryptotanshinone is mediated by distinct JAK/STAT3/5 and SHP1/2
signaling in chronic myeloid leukemia K562 cells. Evid Based
Complement Alternat Med. 2013:8056392013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Liu JJ, Lin DJ, Liu PQ, Huang M, Li XD and
Huang RW: Induction of apoptosis and inhibition of cell adhesive
and invasive effects by tanshinone IIA in acute promyelocytic
leukemia cells in vitro. J Biomed Sci. 13:813–823. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wang JF, Feng JG, Han J, Zhang BB and Mao
WM: The molecular mechanisms of tanshinone IIA on the apoptosis and
arrest of human esophageal carcinoma cells. Biomed Res Int.
2014:5827302014.PubMed/NCBI
|
|
44
|
Tseng PY, Lu WC, Hsieh MJ, Chien SY and
Chen MK: Tanshinone IIA induces apoptosis in human oral cancer KB
cells through a mitochondria-dependent pathway. Biomed Res Int.
2014:5405162014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Shan YF, Shen X, Xie YK, Chen JC, Shi HQ,
Yu ZP, Song QT, Zhou MT and Zhang QY: Inhibitory effects of
tanshinone II-a on invasion and metastasis of human colon carcinoma
cells. Acta Pharmacol Sin. 30:1537–1542. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Su CC: Tanshinone IIA potentiates the
efficacy of 5-FU in colo205 colon cancer cells in vivo through
downregulation of P-gp and LC3-II. Exp Ther Med. 3:555–559.
2012.PubMed/NCBI
|
|
47
|
Hernandez-Flores G, Ortiz-Lazareno PC,
Lerma-Diaz JM, Dominguez-Rodriguez JR, Jave-Suarez LF,
Aguilar-Lemarroy Adel C, de Celis-Carrillo R, del Toro-Arreola S,
Castellanos-Esparza YC and Bravo-Cuellar A: Pentoxifylline
sensitizes human cervical tumor cells to cisplatin-induced
apoptosis by suppressing nf-kappa B and decreased cell senescence.
BMC Cancer. 11:4832011. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Liu T, Liu D, Liu J, Song JT, Gao SL, Li
H, Hu LH and Liu BR: Effect of NF-κB inhibitors on the
chemotherapy-induced apoptosis of the colon cancer cell line HT-29.
Exp Ther Med. 4:716–722. 2012.PubMed/NCBI
|
|
49
|
Wang S, Liu Z, Wang L and Zhang X:
NF-kappaB signaling pathway, inflammation and colorectal cancer.
Cell Mol Immunol. 6:327–334. 2009. View Article : Google Scholar : PubMed/NCBI
|
